Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-552 in mild Alzheimer's disease
NCT05771428Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Jun 2023
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 2 trial of SDI-118 in Alzheimer's disease (AD), sponsored by AbbVie Inc.. Started Jun 2023; status: completed.
02
Drugs
SDI-118
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT05771428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05771428.